Publication: Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells
Issued Date
2018-12-01
Resource Type
ISSN
20411723
Other identifier(s)
2-s2.0-85047190636
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Communications. Vol.9, No.1 (2018)
Suggested Citation
Thomas F. Allison, Peter W. Andrews, Yishai Avior, Ivana Barbaric, Nissim Benvenisty, Christoph Bock, Jennifer Brehm, Oliver Brüstle, Ivan Damjanov, Andrew Elefanty, Daniel Felkner, Paul J. Gokhale, Florian Halbritter, Lyn E. Healy, Tim X. Hu, Barbara B. Knowles, Jeanne F. Loring, Tenneille E. Ludwig, Robyn Mayberry, Suzanne Micallef, Jameelah S. Mohamed, Franz Josef Müller, Christine L. Mummery, Norio Nakatsuji, Elizabeth S. Ng, Steve K.W. Oh, Orla O'Shea, Martin F. Pera, Benjamin Reubinoff, Paul Robson, Janet Rossant, Bernhard M. Schuldt, Davor Solter, Koula Sourris, Glyn Stacey, Edouard G. Stanley, Hirofumi Suemori, Kazutoshi Takahashi, Shinya Yamanaka Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells. Nature Communications. Vol.9, No.1 (2018). doi:10.1038/s41467-018-04011-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/44994
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells
Author(s)
Thomas F. Allison
Peter W. Andrews
Yishai Avior
Ivana Barbaric
Nissim Benvenisty
Christoph Bock
Jennifer Brehm
Oliver Brüstle
Ivan Damjanov
Andrew Elefanty
Daniel Felkner
Paul J. Gokhale
Florian Halbritter
Lyn E. Healy
Tim X. Hu
Barbara B. Knowles
Jeanne F. Loring
Tenneille E. Ludwig
Robyn Mayberry
Suzanne Micallef
Jameelah S. Mohamed
Franz Josef Müller
Christine L. Mummery
Norio Nakatsuji
Elizabeth S. Ng
Steve K.W. Oh
Orla O'Shea
Martin F. Pera
Benjamin Reubinoff
Paul Robson
Janet Rossant
Bernhard M. Schuldt
Davor Solter
Koula Sourris
Glyn Stacey
Edouard G. Stanley
Hirofumi Suemori
Kazutoshi Takahashi
Shinya Yamanaka
Peter W. Andrews
Yishai Avior
Ivana Barbaric
Nissim Benvenisty
Christoph Bock
Jennifer Brehm
Oliver Brüstle
Ivan Damjanov
Andrew Elefanty
Daniel Felkner
Paul J. Gokhale
Florian Halbritter
Lyn E. Healy
Tim X. Hu
Barbara B. Knowles
Jeanne F. Loring
Tenneille E. Ludwig
Robyn Mayberry
Suzanne Micallef
Jameelah S. Mohamed
Franz Josef Müller
Christine L. Mummery
Norio Nakatsuji
Elizabeth S. Ng
Steve K.W. Oh
Orla O'Shea
Martin F. Pera
Benjamin Reubinoff
Paul Robson
Janet Rossant
Bernhard M. Schuldt
Davor Solter
Koula Sourris
Glyn Stacey
Edouard G. Stanley
Hirofumi Suemori
Kazutoshi Takahashi
Shinya Yamanaka
Other Contributor(s)
A-Star, Bioprocessing Technology Institute
The Florey Institute of Neuroscience and Mental Health
The Francis Crick Institute
WiCell Research Institute
A-Star, Genome Institute of Singapore
Max Planck Institute for Molecular Genetics
Hospital for Sick Children University of Toronto
University of Kansas, School of Medicine
Walter and Eliza Hall Institute of Medical Research
University of Melbourne
Royal Children's Hospital, Melbourne
Gladstone Institute of Cardiovascular Disease
Monash University
University of Toronto
Leiden University Medical Center - LUMC
Mahidol University
Medizinische Universitat Wien
Kyoto University
Jackson Laboratory
Hebrew University of Jerusalem
Universität Bonn
Scripps Research Institute
Administrative Headquarters of the Max Planck Society
Universitätsklinikum Schleswig-Holstein Campus Kiel
David Geffen School of Medicine at UCLA
Osterreichische Akademie Der Wissenschaften
University of Sheffield
National Institute for Biological Standards and Control
Max Planck Institut für Informatik
University of Connecticut Health Center
Hadassah University Medical Centre
International Stem Cell Banking Initiative
Jackson Laboratory for Genomic Medicine
The Florey Institute of Neuroscience and Mental Health
The Francis Crick Institute
WiCell Research Institute
A-Star, Genome Institute of Singapore
Max Planck Institute for Molecular Genetics
Hospital for Sick Children University of Toronto
University of Kansas, School of Medicine
Walter and Eliza Hall Institute of Medical Research
University of Melbourne
Royal Children's Hospital, Melbourne
Gladstone Institute of Cardiovascular Disease
Monash University
University of Toronto
Leiden University Medical Center - LUMC
Mahidol University
Medizinische Universitat Wien
Kyoto University
Jackson Laboratory
Hebrew University of Jerusalem
Universität Bonn
Scripps Research Institute
Administrative Headquarters of the Max Planck Society
Universitätsklinikum Schleswig-Holstein Campus Kiel
David Geffen School of Medicine at UCLA
Osterreichische Akademie Der Wissenschaften
University of Sheffield
National Institute for Biological Standards and Control
Max Planck Institut für Informatik
University of Connecticut Health Center
Hadassah University Medical Centre
International Stem Cell Banking Initiative
Jackson Laboratory for Genomic Medicine
Abstract
© 2018 The Author(s). The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.